Drug intelligence / Profile preview

ICE 1207

Development stage: Preclinical
Lead developer: iCeutica
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems

Overview

ICE 1207 is an early-stage oncology drug candidate being developed by iCeutica for the treatment of lung cancer. The drug is a small molecule formulated using iCeutica's proprietary SoluMatrix™ Fine Particle Technology. This technology utilizes a dry milling process to reduce the particle size of active pharmaceutical ingredients to sub-micron levels, which is intended to enhance the solubility and bioavailability of poorly water-soluble compounds. ICE 1207 is currently in the preclinical/lead optimization stage and is available for partnering as part of iCeutica's oncology pipeline.

Beyond the preview

Go deeper on ICE 1207.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICE 1207.

Explore the full profile